The global breast cancer liquid biopsy market size was valued at USD 1.26 billion in 2025 and is projected to grow from USD 1.37 billion in 2026 to USD 2.60 billion by 2034, registering a CAGR of 8.4% during the forecast period from 2026 to 2034. North America dominated the breast cancer liquid biopsy market with a market share of 42.5% in 2025.
Breast cancer liquid biopsy is a minimally invasive testing method that analyzes blood or other body fluids to detect cancer-related materials such as circulating tumor cells and tumor DNA. It can help with early detection, treatment selection, and monitoring of disease progression or recurrence. Demand is growing due to advances in precision medicine, improved testing technologies, and the need for less invasive cancer diagnostic methods.
Download a Free Sample To learn more about this report,
Advancement of Multi-Analyte Liquid Biopsy Technologies
The breast cancer liquid biopsy market is evolving through the development of advanced technologies capable of analyzing multiple cancer-related biomarkers from blood samples. Approaches involving circulating tumor DNA, circulating tumor cells, and other molecular signals are supporting more comprehensive assessments of tumor characteristics. These technological developments are expanding the potential role of liquid biopsy in breast cancer detection, molecular profiling, and disease monitoring.
In March 2026, diagnostic technology developers continued advancing multi-analyte liquid biopsy approaches designed to improve the detection and molecular characterization of breast cancer.
Growing Use of Liquid Biopsy for Treatment Monitoring and Disease Recurrence Surveillance
Liquid biopsy is gaining attention as a minimally invasive approach for monitoring changes in breast cancer over time. Repeated blood-based testing can potentially support the assessment of treatment response, the identification of emerging molecular changes, and surveillance for signs associated with disease recurrence. This growing focus on longitudinal monitoring is expanding the clinical applications of liquid biopsy beyond initial diagnostic assessment.
In July 2026, oncology researchers and diagnostic developers continued evaluating blood-based testing approaches for monitoring treatment response and disease progression in breast cancer patients.
Rising Need for Less Invasive and More Accessible Cancer Testing
Conventional tissue biopsies can require invasive procedures and may not always be practical for repeated testing. The demand for diagnostic approaches that use blood samples and reduce the need for repeated invasive procedures is supporting interest in liquid biopsy technologies. The increasing need for minimally invasive testing options is therefore a fundamental driver of the breast cancer liquid biopsy market.
In April 2026, healthcare providers and diagnostic developers continued emphasizing minimally invasive testing approaches that could support more convenient molecular assessment in oncology care.
High Cost and Limited Reimbursement for Advanced Liquid Biopsy Tests
Advanced liquid biopsy testing can involve sophisticated sequencing technologies, specialized laboratory infrastructure, and complex analytical processes that increase overall testing costs. Limited reimbursement coverage in certain healthcare systems can further restrict patient access and slow the broader adoption of these tests. Financial and reimbursement barriers therefore remain an important restraint for the market.
In June 2026, diagnostic providers continued addressing cost and reimbursement considerations affecting the wider adoption of advanced molecular testing technologies.
Expansion of Liquid Biopsy Applications in Early Breast Cancer Detection
The development of more sensitive blood-based technologies is creating opportunities for liquid biopsy to play a broader role in identifying breast cancer at earlier stages. Earlier detection applications could significantly expand the potential use of liquid biopsy beyond monitoring patients with established disease. Continued progress in analytical sensitivity and biomarker identification represents an important growth opportunity for the market.
In September 2026, researchers continued investigating highly sensitive blood-based approaches for detecting cancer-associated molecular signals at earlier stages of disease.
Achieving Consistent Analytical Accuracy Across Diverse Patient Populations
The detection of cancer-related biomarkers in blood can be influenced by tumor characteristics, disease stage, biomarker abundance, and biological variation among patients. Ensuring consistent sensitivity, specificity, and reproducibility across diverse patient populations remains technically challenging, particularly when detecting low concentrations of cancer-derived material. Maintaining reliable analytical performance is therefore a significant challenge for the breast cancer liquid biopsy market.
In November 2026, diagnostic researchers continued focusing on improving analytical validation and test reproducibility for highly sensitive blood-based cancer detection technologies.
Circulating Cell-free DNA (cfDNA) Segment Dominated the Market with 45.8% Share in 2025
The circulating cell-free DNA (cfDNA) segment dominated the global breast cancer liquid biopsy market with a 45.8% share in 2025. cfDNA testing enables the detection of tumor-related genetic changes through blood samples, providing a less invasive approach compared with traditional tissue biopsies. Its growing use in molecular profiling, disease monitoring, and treatment planning continues to strengthen the segment's leading position.
Circulating tumor cells accounted for 29.6% and are used to provide information about tumor progression and treatment response. Extracellular vesicles are growing at the highest CAGR of 18.14%, supported by increasing research into their potential to carry tumor-related molecular information. Advancements in biomarker detection technologies are supporting breast cancer liquid biopsy market growth across different circulating biomarkers.
Request Customizationto receive a tailored report.
Monitoring Segment Dominated the Market with 29.2% Share in 2025
The monitoring segment dominated the global breast cancer liquid biopsy market with a 29.2% share in 2025. Liquid biopsy enables repeated testing through blood samples, making it useful for monitoring disease progression, evaluating treatment response, and identifying molecular changes during therapy. Its minimally invasive nature makes repeated testing more practical during long-term patient management.
Early detection/screening accounted for 25.4% and is growing at the highest CAGR of 18.92%. Increasing research into identifying cancer-related biomarkers at earlier stages is supporting the development of liquid biopsy approaches for screening.
Treatment selection also represents a significant application as molecular information can help guide targeted treatment decisions. Diagnosis accounted for 21.8%, with continued improvements in testing sensitivity and biomarker analysis supporting breast cancer liquid biopsy market demand across clinical applications.
Speak to an Analystto discuss market opportunities.
North America breast cancer liquid biopsy market accounted for 42.5% of the global market, reaching approximately USD 0.54 billion in 2025, and is projected to grow at a CAGR of 14.92% during the forecast period. Strong adoption of advanced cancer diagnostics, growing use of precision medicine, and increasing availability of molecular testing technologies are supporting regional growth. Liquid biopsy is gaining importance for detecting circulating tumor DNA and other biomarkers that can support treatment selection and disease monitoring.
The US market was valued at USD 0.46 billion in 2025, making it the largest contributor in North America. Strong cancer research activities, advanced diagnostic infrastructure, and increasing adoption of genomic and molecular testing continue to support market growth.
Canada's market reached USD 0.08 billion in 2025. Increasing access to advanced cancer diagnostics, growing precision oncology research, and adoption of minimally invasive testing methods are supporting market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe breast cancer liquid biopsy market accounted for 27.3% of the global market, reaching approximately USD 0.34 billion in 2025, and is expected to register a CAGR of 15.21% during the forecast period. Increasing cancer screening and research activities, improvements in molecular diagnostics, and growing adoption of personalized treatment approaches are supporting regional demand. Healthcare providers are increasingly exploring liquid biopsy technologies for therapy selection and monitoring treatment response.
Germany's market accounted for USD 0.10 billion in 2025. Advanced oncology infrastructure, strong clinical research capabilities, and increasing adoption of precision diagnostic technologies continue to support market growth.
The UK market was valued at USD 0.07 billion in 2025. Growing cancer research, increasing use of genomic testing, and continued development of minimally invasive diagnostic approaches are contributing to market expansion.
Asia Pacific breast cancer liquid biopsy market accounted for 21.4% of the global market, reaching approximately USD 0.27 billion in 2025, and is projected to register the fastest regional CAGR of 18.67% during the forecast period. Improving healthcare infrastructure, growing awareness of early cancer detection, increasing diagnostic investment, and expansion of precision medicine are driving regional growth. Rising availability of molecular diagnostic laboratories is further improving access to advanced testing technologies.
Japan's market generated USD 0.05 billion in 2025. Advanced healthcare infrastructure, strong cancer research capabilities, and increasing use of genomic and precision diagnostic technologies continue to support market development.
China's market accounted for USD 0.14 billion in 2025, making it a major contributor within Asia Pacific. Expanding cancer diagnostics, growing biotechnology investment, increasing molecular testing capabilities, and greater focus on early cancer detection continue to drive market demand.
Middle East & Africa breast cancer liquid biopsy market accounted for 3.6% of the global market, reaching approximately USD 0.05 billion in 2025, and is anticipated to grow at a CAGR of 14.35% during the forecast period. Improving oncology infrastructure, increasing awareness of breast cancer screening, and investment in advanced diagnostic technologies are supporting regional development.
The UAE market was valued at USD 0.02 billion in 2025. Investment in advanced oncology services, increasing access to molecular diagnostics, and growing adoption of precision medicine approaches continue to support market growth.
The global Breast Cancer Liquid Biopsy market is highly competitive, driven by growing demand for minimally invasive cancer diagnostics, early disease detection, and personalized treatment monitoring. Key players include QIAGEN, NeoGenomics Laboratories, The Menarini Group, Biocept Inc., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Epic Sciences Inc., Myriad Genetics Inc., Fluxion Biosciences Inc., Illumina, Bio-Rad Laboratories, Cynvenio, Biosystems Inc., Genomic Health Inc., Thermo Fisher Scientific Inc., Biodesix Inc., Guardant Health Inc., and Isogen Life Science B.V. Companies are focusing on circulating tumor DNA, circulating tumor cell analysis, next-generation sequencing, and advanced molecular diagnostic technologies to improve cancer detection and treatment decisions.
QIAGEN: An Emerging Market Leader
QIAGEN has strengthened its position through its molecular testing and liquid biopsy technologies designed to analyze circulating biomarkers from blood samples. The company focuses on sensitive biomarker detection, advanced sample preparation, and molecular diagnostic solutions that support cancer research and precision oncology. These capabilities support QIAGEN’s strong position in the global breast cancer liquid biopsy market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com